[First experience with elbasvir/grazoprevir fixed-dose combination in real-life practice in the Czech Republic]
{{output}}
Hepatitis C virus infection (HCV) is one of the leading causes of chronic liver disease worldwide. The new fixed-dose combination of the highly potent second wave first generation NS5A inhibitor elbasvir (50 mg) and the second generation protease inhibitor gra... ...
